Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 3/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 2/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | MARK3 | P27448 | 3/20 | 0.32 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29714346 | 1.00 | MEN1 (0.44) | MEN1KMT2AKDM4EMAPTTHRB | |
| SCHEMBL29714341 | 1.00 | MEN1 (0.44) | MEN1KMT2AKDM4EMAPTTHRB | |
| SCHEMBL25538733 | 0.95 | MEN1 (0.38) | MEN1KMT2AKDM4EMAPTTHRB | |
| SCHEMBL29990662 | 0.82 | KMT2A (0.43) | MEN1KMT2AKDM4EMAPTTHRB | |
| SCHEMBL22174938 | 0.82 | KMT2A (0.43) | MEN1KMT2AKDM4EMAPTTHRB | |
| SCHEMBL22184578 | 0.81 | KMT2A (0.42) | MEN1KMT2AKDM4EMAPTTHRB | |
| SCHEMBL3971391 | 0.80 | HCAR1 (0.34) | FGFR4 | |
| SCHEMBL30883472 | 0.79 | FGFR4 (0.45) | MEN1KMT2AKDM4EMAPTTHRB | |
| SCHEMBL27225133 | 0.79 | FGFR4 (0.45) | MEN1KMT2AKDM4EMAPTTHRB | |
| SCHEMBL3967401 | 0.78 | FGFR4 (0.48) | MEN1KMT2AKDM4EMAPTFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124464-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2024-04-18 | — | — | US | disclosed |
| CN-116529251-A | Substituted fused bicyclic compounds as kinase inhibitors and their use | 上海瑛派药业有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2022116943-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | 上海瑛派药业有限公司 | 2022-06-09 | — | — | WO | disclosed |
| WO-2022116943-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | 上海瑛派药业有限公司 | 2022-06-09 | — | — | WO | disclosed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1080092-B1 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | MEN1 4287/4885KMT2A 2878/4885KDM4E 3108/4885 |
| US-20240124464-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | NUAK1, NUAK2, NEK11 | MEN1 1440/4885KMT2A 897/4885KDM4E 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.